Up next

Autoplay

FL: Switching to Bendamustine/Rituximab at Progression

0 Views • 08/26/25
Share
Side Effects
Side Effects
Subscribers
0

Peter Martin, MD, evaluates the decision to treat a patient with bendamustine/rituximab in the context of high-risk follicular lymphoma that has progressed following frontline R-CHOP therapy and rituximab maintenance.

For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/

Show more
0 Comments sort Sort By

Up next

Autoplay